 Daniel Olson
Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dengue | 4 | 2024 | 80 | 1.520 |
Why?
| | Guatemala | 19 | 2025 | 327 | 1.480 |
Why?
| | Zika Virus Infection | 6 | 2024 | 165 | 1.400 |
Why?
| | Arbovirus Infections | 2 | 2019 | 21 | 1.180 |
Why?
| | Microcephaly | 4 | 2024 | 98 | 1.120 |
Why?
| | Caliciviridae Infections | 2 | 2018 | 20 | 1.110 |
Why?
| | Norovirus | 2 | 2018 | 26 | 1.110 |
Why?
| | Zika Virus | 5 | 2024 | 128 | 1.100 |
Why?
| | Dengue Virus | 4 | 2024 | 52 | 1.100 |
Why?
| | Viral Vaccines | 2 | 2018 | 98 | 1.070 |
Why?
| | Gastroenteritis | 2 | 2017 | 69 | 1.030 |
Why?
| | Disease Outbreaks | 4 | 2024 | 395 | 0.870 |
Why?
| | Vital Signs | 2 | 2013 | 43 | 0.810 |
Why?
| | Rural Population | 10 | 2025 | 567 | 0.770 |
Why?
| | Triage | 2 | 2013 | 224 | 0.680 |
Why?
| | Hospitals | 4 | 2016 | 691 | 0.670 |
Why?
| | Stevens-Johnson Syndrome | 2 | 2017 | 39 | 0.670 |
Why?
| | Sentinel Surveillance | 2 | 2017 | 49 | 0.660 |
Why?
| | Child Development | 5 | 2025 | 475 | 0.650 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2018 | 1330 | 0.630 |
Why?
| | Global Health | 2 | 2022 | 386 | 0.630 |
Why?
| | Fever | 2 | 2017 | 306 | 0.610 |
Why?
| | Public Health | 2 | 2019 | 588 | 0.520 |
Why?
| | Cell Phone | 1 | 2017 | 76 | 0.520 |
Why?
| | Infant | 20 | 2025 | 9482 | 0.510 |
Why?
| | Health Policy | 1 | 2019 | 388 | 0.470 |
Why?
| | Encephalomyelitis, Acute Disseminated | 1 | 2015 | 11 | 0.470 |
Why?
| | Typhoid Fever | 1 | 2015 | 10 | 0.470 |
Why?
| | Health Information Systems | 1 | 2015 | 17 | 0.460 |
Why?
| | Severity of Illness Index | 2 | 2013 | 2836 | 0.460 |
Why?
| | Meningitis, Bacterial | 1 | 2015 | 47 | 0.450 |
Why?
| | Mobile Applications | 1 | 2017 | 183 | 0.450 |
Why?
| | Paralysis | 1 | 2015 | 71 | 0.450 |
Why?
| | Malaria | 1 | 2015 | 63 | 0.440 |
Why?
| | Child, Preschool | 18 | 2025 | 11105 | 0.440 |
Why?
| | Population Surveillance | 1 | 2017 | 482 | 0.420 |
Why?
| | Neuromyelitis Optica | 1 | 2015 | 132 | 0.410 |
Why?
| | Allied Health Personnel | 1 | 2013 | 46 | 0.400 |
Why?
| | Communicable Diseases | 1 | 2015 | 159 | 0.390 |
Why?
| | Growth Disorders | 2 | 2023 | 86 | 0.380 |
Why?
| | Developing Countries | 2 | 2019 | 308 | 0.380 |
Why?
| | Health Resources | 1 | 2013 | 121 | 0.380 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 807 | 0.380 |
Why?
| | Hospital Mortality | 2 | 2013 | 911 | 0.370 |
Why?
| | Hospitalization | 4 | 2015 | 2200 | 0.360 |
Why?
| | Serogroup | 3 | 2025 | 44 | 0.320 |
Why?
| | Child | 13 | 2022 | 21989 | 0.320 |
Why?
| | Streptococcus pneumoniae | 2 | 2025 | 169 | 0.320 |
Why?
| | Databases, Factual | 1 | 2015 | 1357 | 0.310 |
Why?
| | Infant, Newborn | 12 | 2025 | 6084 | 0.300 |
Why?
| | Humans | 37 | 2025 | 137782 | 0.290 |
Why?
| | HIV Infections | 4 | 2015 | 2837 | 0.280 |
Why?
| | Mycoplasma pneumoniae | 2 | 2017 | 57 | 0.270 |
Why?
| | Family Characteristics | 2 | 2018 | 191 | 0.260 |
Why?
| | Cross-Sectional Studies | 5 | 2022 | 5478 | 0.250 |
Why?
| | Seroepidemiologic Studies | 2 | 2024 | 165 | 0.240 |
Why?
| | Community-Acquired Infections | 2 | 2025 | 174 | 0.230 |
Why?
| | Ectoparasitic Infestations | 1 | 2024 | 5 | 0.230 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2025 | 48 | 0.230 |
Why?
| | Animals, Domestic | 1 | 2024 | 17 | 0.230 |
Why?
| | Antigens, Bacterial | 1 | 2025 | 127 | 0.220 |
Why?
| | Acute Disease | 2 | 2017 | 1007 | 0.220 |
Why?
| | Head | 1 | 2025 | 105 | 0.220 |
Why?
| | Male | 21 | 2025 | 67906 | 0.220 |
Why?
| | Culex | 1 | 2023 | 16 | 0.210 |
Why?
| | Prospective Studies | 9 | 2025 | 7623 | 0.210 |
Why?
| | Malawi | 5 | 2014 | 53 | 0.210 |
Why?
| | Aedes | 1 | 2023 | 65 | 0.200 |
Why?
| | Vomiting | 1 | 2023 | 130 | 0.190 |
Why?
| | Cross Reactions | 1 | 2022 | 133 | 0.190 |
Why?
| | Cough | 1 | 2023 | 122 | 0.190 |
Why?
| | Viruses | 1 | 2023 | 113 | 0.190 |
Why?
| | Diarrhea | 1 | 2023 | 184 | 0.190 |
Why?
| | Masks | 1 | 2022 | 63 | 0.190 |
Why?
| | Adolescent | 7 | 2018 | 21574 | 0.190 |
Why?
| | Neurodevelopmental Disorders | 1 | 2024 | 181 | 0.190 |
Why?
| | Female | 20 | 2025 | 73465 | 0.170 |
Why?
| | Yellow fever virus | 1 | 2020 | 4 | 0.170 |
Why?
| | Yellow Fever | 1 | 2020 | 8 | 0.170 |
Why?
| | Neuropsychological Tests | 3 | 2020 | 1025 | 0.170 |
Why?
| | Health Services Research | 2 | 2013 | 404 | 0.170 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2022 | 853 | 0.160 |
Why?
| | Language Tests | 1 | 2019 | 23 | 0.160 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2020 | 346 | 0.150 |
Why?
| | Language Development Disorders | 1 | 2019 | 41 | 0.150 |
Why?
| | Americas | 1 | 2019 | 28 | 0.150 |
Why?
| | Motor Skills | 1 | 2020 | 97 | 0.150 |
Why?
| | Dengue Vaccines | 1 | 2018 | 10 | 0.150 |
Why?
| | Arboviruses | 1 | 2018 | 16 | 0.150 |
Why?
| | Antibodies, Viral | 1 | 2022 | 628 | 0.150 |
Why?
| | Sensitivity and Specificity | 4 | 2020 | 1946 | 0.150 |
Why?
| | Cities | 2 | 2016 | 133 | 0.140 |
Why?
| | Surveys and Questionnaires | 3 | 2021 | 5793 | 0.140 |
Why?
| | Chlamydophila pneumoniae | 1 | 2017 | 13 | 0.140 |
Why?
| | Mycoplasma Infections | 1 | 2017 | 16 | 0.140 |
Why?
| | Chikungunya Fever | 1 | 2018 | 79 | 0.140 |
Why?
| | Referral and Consultation | 2 | 2013 | 786 | 0.140 |
Why?
| | Mouth Mucosa | 1 | 2017 | 92 | 0.130 |
Why?
| | Antigens, Viral | 1 | 2017 | 178 | 0.130 |
Why?
| | Pneumonia, Mycoplasma | 1 | 2017 | 57 | 0.130 |
Why?
| | Cohort Studies | 4 | 2025 | 5750 | 0.130 |
Why?
| | RNA, Viral | 1 | 2020 | 656 | 0.130 |
Why?
| | Analgesia, Obstetrical | 1 | 2016 | 20 | 0.130 |
Why?
| | Neonatal Screening | 1 | 2017 | 169 | 0.120 |
Why?
| | Analgesia, Epidural | 1 | 2016 | 33 | 0.120 |
Why?
| | Learning | 1 | 2020 | 409 | 0.120 |
Why?
| | ROC Curve | 2 | 2017 | 554 | 0.120 |
Why?
| | Point-of-Care Systems | 2 | 2014 | 167 | 0.120 |
Why?
| | Risk Factors | 3 | 2025 | 10407 | 0.120 |
Why?
| | Hospitals, Pediatric | 2 | 2017 | 509 | 0.120 |
Why?
| | Reference Values | 2 | 2014 | 816 | 0.110 |
Why?
| | Data Collection | 1 | 2018 | 673 | 0.110 |
Why?
| | Pneumococcal Infections | 1 | 2016 | 115 | 0.110 |
Why?
| | Clinical Medicine | 1 | 2014 | 25 | 0.110 |
Why?
| | Travel | 1 | 2015 | 130 | 0.110 |
Why?
| | Chickens | 2 | 2024 | 191 | 0.110 |
Why?
| | CD4 Lymphocyte Count | 1 | 2014 | 269 | 0.100 |
Why?
| | Caregivers | 1 | 2021 | 888 | 0.100 |
Why?
| | Clinical Laboratory Techniques | 1 | 2014 | 97 | 0.100 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2014 | 105 | 0.100 |
Why?
| | Child, Hospitalized | 1 | 2013 | 49 | 0.100 |
Why?
| | Area Under Curve | 1 | 2013 | 314 | 0.100 |
Why?
| | Confidence Intervals | 1 | 2013 | 329 | 0.100 |
Why?
| | Respiration | 1 | 2013 | 199 | 0.100 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2014 | 184 | 0.090 |
Why?
| | Anti-Retroviral Agents | 1 | 2014 | 233 | 0.090 |
Why?
| | Psychometrics | 3 | 2021 | 720 | 0.090 |
Why?
| | Survival Analysis | 1 | 2015 | 1325 | 0.090 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2016 | 394 | 0.090 |
Why?
| | Reproducibility of Results | 4 | 2021 | 3290 | 0.090 |
Why?
| | Workload | 1 | 2013 | 167 | 0.090 |
Why?
| | Aged, 80 and over | 1 | 2023 | 7637 | 0.090 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2013 | 262 | 0.080 |
Why?
| | Odds Ratio | 1 | 2013 | 1070 | 0.080 |
Why?
| | Ambulatory Care Facilities | 1 | 2012 | 235 | 0.080 |
Why?
| | Temperature | 1 | 2013 | 679 | 0.080 |
Why?
| | Health Personnel | 2 | 2014 | 711 | 0.080 |
Why?
| | Sepsis | 1 | 2016 | 617 | 0.080 |
Why?
| | Anti-Bacterial Agents | 2 | 2017 | 1809 | 0.080 |
Why?
| | Heart Rate | 1 | 2013 | 824 | 0.080 |
Why?
| | Oxygen | 1 | 2013 | 938 | 0.070 |
Why?
| | Adult | 6 | 2025 | 38023 | 0.070 |
Why?
| | Logistic Models | 1 | 2013 | 2075 | 0.070 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2014 | 1091 | 0.070 |
Why?
| | Pneumonia | 1 | 2013 | 639 | 0.070 |
Why?
| | Communication | 1 | 2013 | 879 | 0.070 |
Why?
| | Algorithms | 1 | 2014 | 1704 | 0.060 |
Why?
| | Animals | 4 | 2024 | 36951 | 0.060 |
Why?
| | Inflammation | 1 | 2017 | 2838 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2013 | 3569 | 0.060 |
Why?
| | Anaplasma | 1 | 2024 | 2 | 0.060 |
Why?
| | Ehrlichia | 1 | 2024 | 3 | 0.060 |
Why?
| | Rickettsia | 1 | 2024 | 9 | 0.060 |
Why?
| | Bartonella | 1 | 2024 | 7 | 0.060 |
Why?
| | Siphonaptera | 1 | 2024 | 15 | 0.060 |
Why?
| | Delivery of Health Care | 1 | 2012 | 951 | 0.060 |
Why?
| | Ticks | 1 | 2024 | 25 | 0.060 |
Why?
| | Quality Improvement | 1 | 2013 | 1181 | 0.060 |
Why?
| | Cats | 1 | 2024 | 210 | 0.060 |
Why?
| | South America | 1 | 2024 | 60 | 0.050 |
Why?
| | Dog Diseases | 1 | 2024 | 64 | 0.050 |
Why?
| | Mosquito Vectors | 1 | 2023 | 30 | 0.050 |
Why?
| | Dogs | 1 | 2024 | 413 | 0.050 |
Why?
| | Brain | 1 | 2015 | 2677 | 0.050 |
Why?
| | Pregnancy | 3 | 2024 | 6771 | 0.050 |
Why?
| | Personal Protective Equipment | 1 | 2022 | 52 | 0.050 |
Why?
| | Swine | 1 | 2024 | 775 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2022 | 117 | 0.050 |
Why?
| | Mammals | 1 | 2023 | 283 | 0.050 |
Why?
| | Anthropometry | 1 | 2022 | 213 | 0.050 |
Why?
| | International Cooperation | 1 | 2022 | 198 | 0.040 |
Why?
| | Respiratory Tract Infections | 1 | 2025 | 390 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2025 | 1290 | 0.040 |
Why?
| | Paraguay | 1 | 2020 | 3 | 0.040 |
Why?
| | Sri Lanka | 1 | 2020 | 7 | 0.040 |
Why?
| | Endemic Diseases | 1 | 2020 | 32 | 0.040 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2020 | 42 | 0.040 |
Why?
| | Translations | 1 | 2020 | 17 | 0.040 |
Why?
| | Regression Analysis | 1 | 2022 | 1024 | 0.040 |
Why?
| | Child Language | 1 | 2019 | 20 | 0.040 |
Why?
| | Translating | 1 | 2019 | 43 | 0.040 |
Why?
| | Rural Health | 1 | 2019 | 80 | 0.040 |
Why?
| | Culturally Competent Care | 1 | 2019 | 63 | 0.040 |
Why?
| | Viral Load | 1 | 2020 | 469 | 0.040 |
Why?
| | Chromatography, Affinity | 1 | 2017 | 88 | 0.030 |
Why?
| | United States | 1 | 2015 | 14870 | 0.030 |
Why?
| | Epitope Mapping | 1 | 2017 | 62 | 0.030 |
Why?
| | Contact Tracing | 1 | 2017 | 27 | 0.030 |
Why?
| | Molecular Epidemiology | 1 | 2017 | 68 | 0.030 |
Why?
| | Macrolides | 1 | 2017 | 65 | 0.030 |
Why?
| | Sequence Alignment | 1 | 2017 | 343 | 0.030 |
Why?
| | Colorado | 2 | 2017 | 4576 | 0.030 |
Why?
| | Microbial Sensitivity Tests | 1 | 2017 | 361 | 0.030 |
Why?
| | Pneumococcal Vaccines | 1 | 2016 | 142 | 0.030 |
Why?
| | Young Adult | 2 | 2024 | 13240 | 0.030 |
Why?
| | World Health Organization | 1 | 2014 | 123 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2017 | 2139 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1639 | 0.030 |
Why?
| | Random Allocation | 1 | 2014 | 353 | 0.030 |
Why?
| | Urban Population | 1 | 2016 | 479 | 0.030 |
Why?
| | HIV | 1 | 2012 | 234 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1430 | 0.020 |
Why?
| | DNA, Viral | 1 | 2012 | 364 | 0.020 |
Why?
| | Inpatients | 1 | 2014 | 500 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1062 | 0.020 |
Why?
| | Middle Aged | 2 | 2017 | 33554 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2016 | 15682 | 0.010 |
Why?
|
|
Olson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|